Markets are sure the Fed will cut in September, but the path from there is much murkier

Markets are sure the Fed will cut in September, but the path from there is much murkier


Key Points
  • Friday’s booming rally turned into Monday’s reality check as investors weighed just how aggressive the Federal Reserve will be on lowering interest rates.
  • The implied probability for another cut in October was just 42%. That second cut is about fully priced in for December, but there’s just a 33% expectation for three total moves this year.
  • There are ongoing questions about the impact of Fed rates in the current climate.



Source

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more
Finance

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more

Check out the companies making the biggest moves midday: KLA Corp. — The semiconductor equipment maker jumped 4%, nearing a 52-week high, after Jefferies raised its 12-month price target to $1,500 from $1,200, saying “AI continues to drive spend with [wafer fab equipment] accelerating into C26/C27,” and citing KLA’s “outsized exposure to the Leading Edge.” […]

Read More
Hassett’s Fed chair candidacy received pushback from high-level people close to Trump, sources say
Finance

Hassett’s Fed chair candidacy received pushback from high-level people close to Trump, sources say

watch now VIDEO5:4705:47 The race for the next Fed chair: Here’s the latest Squawk Box Kevin Hassett’s candidacy for the Federal Reserve chair, once seen by the market as almost a sure thing, has received some pushback by high-level people who have the ear of President Donald Trump, according to sources familiar with the matter. […]

Read More
Stocks making the biggest moves premarket: iRobot, Las Vegas Sands, Tilray & more
Finance

Stocks making the biggest moves premarket: iRobot, Las Vegas Sands, Tilray & more

Check out the companies making headlines before the bell. Tilray — The cannabis stock jumped about 3%, building on last week’s rally sparked by news that President Donald Trump would instruct federal agencies to give the drug a less-stringent Schedule III classification from its current Schedule I designation. Dollar General — Shares rose 3% after […]

Read More